Pharmalot

Pharmalot Ed Silverman

STAT Plus: Pharma loses a court battle in its bid to block states from importing drugs from Canada

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Biden to call for expanding caps on insulin prices; families seek to override Vertex CF drug patents in organized campaign

Pharmalot Ed Silverman

STAT Plus: Angry at Vertex pricing of cystic fibrosis drugs, families in four countries seek to override patents

Pharma Ed Silverman

STAT Plus: Pharmalittle: AbbVie to lift $2B cap on deals as Humira rivals appear; India to spend $80M to bolster regulatory system

Pharmalot Ed Silverman

STAT Plus: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links to drug-resistant infections

Pharmalot Ed Silverman and Andrew Joseph

STAT Plus: Leading ALS advocacy group roiled by infighting over money and priorities

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: GSK CEO warns U.K. pharma industry is at a ‘tipping point’; Gavi tussles with vaccine makers over refunds

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program

Pharmalot Ed Silverman

STAT Plus: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients

Pharmalot Ed Silverman

STAT Plus: U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine

Pharmalot Ed Silverman

STAT Plus: Pharma wins a key round in a court battle with hospitals over a drug discount program

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pfizer is scolded by U.K. industry group over CEO’s remarks on vaccination; Amgen to lay off 300 U.S. employees

Pharmalot Ed Silverman

STAT Plus: ‘A classic case’: A legal expert explains why lawsuits challenging abortion pill restrictions may succeed

Pharmalot Ed Silverman

STAT Plus: Pfizer is scolded by a U.K. trade group for remarks its CEO made about vaccination

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Some Republicans push to probe Pfizer over Covid-19 ‘mutations’; Warren urges FTC to probe pharma mergers

Pharmalot Ed Silverman

STAT Plus: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients

Pharmalot Ed Silverman

STAT Plus: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Strange bedfellows lobby for Medicare coverage of obesity drugs; FDA working with WHO to probe cough syrups

Pharmalot Ed Silverman

STAT Plus: Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad

Pharmalot Ed Silverman

STAT Plus: Novartis is fined by Belgian regulators for anticompetitive practices over an eye treatment

Pharmalot Ed Silverman

STAT Plus: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Amazon adds $5 monthly generic drug subscription; PhRMA ends lobbying contract with brother of White House official

Pharmalot Ed Silverman

STAT Plus: Many pediatric drug study results were never posted to a U.S. government database

Pharmalot Ed Silverman

STAT Plus: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity